Indacaterol/glycopyrronium bromide
Jump to navigation
Jump to search
Combination of | |
---|---|
Indacaterol | Ultra-long-acting beta-adrenoceptor agonist |
Glycopyrronium bromide | Muscarinic anticholinergic |
Clinical data | |
Trade names | Ultibro Breezhaler, Utibron Neohaler, Xoterna Breezhaler |
Pregnancy category |
|
Routes of administration | Inhalation only |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
KEGG | |
CompTox Dashboard (EPA) |
Indacaterol/glycopyrronium bromide, sold under the brand name Ultibro Breezhaler among others, is a fixed-dose combination medication for inhalation consisting of the following two active ingredients:
- Indacaterol maleate—an ultra-long-acting beta-adrenoceptor agonist (ultra-LABA);[1]
- Glycopyrronium bromide (glycopyrrolate)—a muscarinic anticholinergic.
Indacaterol maleate/glycopyrronium bromide is used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).[2]
The drug is marketed by Novartis under the trade names Ultibro Breezhaler and Utibron Neohaler in Europe and the United States, respectively.[2][3] In 2016, Novartis licensed its U.S. commercial rights for Seebri Neohaler and Utibron Neohaler to Sunovion Pharmaceuticals.[4]
References
- ^ Cazzola M, Matera MG, Lötvall J (July 2005). "Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease". Expert Opin Investig Drugs. 14 (7): 775–83. doi:10.1517/13543784.14.7.775. PMID 16022567. S2CID 11930383.
- ^ a b "Ultibro Breezhaler". medicines.org.uk. DataPharm. 3 February 2015. Retrieved 9 February 2015.
- ^ "Approval History: NDA 207930". DRUGS@FDA. US FDA. Retrieved 14 May 2016.
- ^ Faulkner, Sarah (22 December 2016). "Sunovion, Novartis ink licensing deal for inhaled COPD drugs". Drug Delivery Business.
External links
- "Glycopyrrolate mixture with indacaterol". Drug Information Portal. U.S. National Library of Medicine.
Categories:
- Articles with short description
- Short description is different from Wikidata
- Use dmy dates from August 2021
- Drugs with non-standard legal status
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Beta-adrenergic agonists
- Combination asthma drugs
- Muscarinic antagonists
- Drugs developed by Novartis
- All stub articles
- Respiratory system drug stubs